Description

Monalisa Mild with Lidocaine

Monalisa Mild is a professional injectable dermal filler containing cross-linked hyaluronic acid and lidocaine. Its balanced gel characteristics are designed for the temporary correction of suitable facial lines and the restoration of subtle facial volume.

Each prefilled syringe contains 1ml of transparent hyaluronic acid gel formulated with 24mg/ml of cross-linked hyaluronic acid and 0.3% lidocaine. The incorporated lidocaine is intended to help improve patient comfort during administration.

Monalisa Mild is manufactured in South Korea by Genoss Co., Ltd. It is intended exclusively for administration by appropriately qualified, trained and insured healthcare or aesthetic professionals.

What Is Monalisa Mild Used For?

Monalisa Mild occupies the intermediate position between Monalisa Soft and the firmer products in the Monalisa collection. The manufacturer identifies it for professional placement within the superficial dermis or middle layer of the subcutaneous tissue, depending on the treatment indication and individual patient anatomy.

Published product information associates Monalisa Mild with the professional correction of suitable perioral lines, forehead lines and selected areas requiring subtle cheek volume. It may also be considered for appropriate lip treatments following a complete clinical assessment.

These are general product indications rather than treatment recommendations for every patient. The treating practitioner must determine whether the product, treatment area and intended placement are suitable after reviewing the patient’s anatomy, medical history and expectations.

Monalisa Mild Product Specifications

• Product: Monalisa Mild with Lidocaine
• Product type: Injectable hyaluronic acid dermal filler
• Syringe volume: 1ml
• Hyaluronic acid concentration: 24mg/ml
• Lidocaine concentration: 0.3%
• Particle size: Approximately 400 micrometres
• Recommended placement: Superficial dermis or middle layer of subcutaneous tissue
• Needles: Commonly supplied with two 27G thin-wall needles
• Manufacturer: Genoss Co., Ltd.
• Country of manufacture: South Korea
• Storage: 2°C to 25°C
• Use: Qualified professional use only

Needle sizes and packaging configurations can vary between markets. Always check the exact carton supplied before publishing or relying on these specifications.

Key Features of Monalisa Mild

• Contains 24mg/ml of cross-linked hyaluronic acid
• Includes 0.3% lidocaine for improved treatment comfort
• Approximately 400-micrometre particle profile
• Designed for balanced correction and subtle volume restoration
• Suitable for selected superficial-to-intermediate professional applications
• Supplied in a sterile, ready-to-use 1ml syringe
• Manufactured using Monalisa Hy-BRID technology
• Ergonomic syringe design intended to support controlled administration

Cross-Linked Hyaluronic Acid Technology

Hyaluronic acid is naturally present within the human body, where it contributes to tissue hydration and structure. In dermal fillers, cross-linking transforms hyaluronic acid into a gel that can provide temporary physical support when correctly placed in suitable tissue.

Monalisa Mild is manufactured using Genoss Hy-BRID technology. According to the manufacturer, this process is designed to produce dense and uniform hyaluronic acid particles with balanced viscoelastic properties.

The gel is not permanent and will gradually break down over time. The appearance and duration of any correction can vary significantly according to the treatment area, product quantity, placement, patient metabolism, lifestyle and other individual factors. No particular duration or aesthetic result can be guaranteed.

Monalisa Mild Compared with Other Monalisa Fillers

The Monalisa Lidocaine collection includes several formulations with different particle sizes and intended placement profiles:

• Monalisa Soft: Approximately 200-micrometre particles for superficial placement
• Monalisa Mild: Approximately 400-micrometre particles for superficial or intermediate placement
• Monalisa Hard: Approximately 600-micrometre particles for middle-to-deeper placement
• Monalisa Ultra: Approximately 900-micrometre particles for deeper professional applications

Monalisa Mild offers a balance between the delicate characteristics of Soft and the stronger volumising properties of Hard or Ultra. Product selection should be based on the intended indication, tissue depth, required support and the practitioner’s professional assessment.

Professional Consultation and Treatment Planning

Before using Monalisa Mild, the practitioner must complete a detailed consultation and suitability assessment. This should cover the patient’s medical history, allergies, medication, previous aesthetic procedures, current skin condition and treatment expectations.

The patient should receive clear information about the proposed treatment, realistic limitations, possible side effects, aftercare requirements and alternative options. Informed consent should be obtained before treatment, and the product’s batch number and traceability label should be recorded in the patient’s notes.

Important Safety Information

Monalisa Mild must never be injected into a blood vessel. Accidental intravascular administration of dermal filler can cause serious complications, including vascular occlusion, tissue ischaemia, necrosis, visual impairment, blindness or stroke.

Administration requires comprehensive anatomical knowledge, aseptic technique and the ability to identify and manage complications immediately. Practitioners must follow the current manufacturer’s instructions and maintain appropriate emergency procedures and supplies.

Do not use Monalisa Mild in patients with a known hypersensitivity to hyaluronic acid, lidocaine, amide-type local anaesthetics or another product component. Treatment should not be performed in areas affected by active infection, inflammation, irritation, broken skin, active cold sores or untreated skin disease.

Patients who are pregnant or breastfeeding, taking anticoagulants, affected by bleeding or immune disorders, prone to significant scarring, or who have a history of severe allergies require careful professional assessment. The manufacturer’s complete contraindications and warnings must be reviewed before treatment.

Possible Treatment Reactions

Temporary injection-site reactions can include redness, swelling, tenderness, bruising, itching, firmness, discolouration or mild discomfort. These reactions do not represent every possible adverse event.

Patients should receive written aftercare instructions and clear guidance explaining when urgent assessment is necessary. Unexpected pain, skin blanching, colour changes, visual symptoms or neurological symptoms require immediate professional attention.

Storage, Handling and Traceability

Store Monalisa Mild between 2°C and 25°C unless the exact packaging supplied states otherwise. Do not freeze the product or expose it to excessive heat.

Inspect the outer carton, sterile barrier, syringe, gel, batch number and expiry date before use. Do not use the product if the packaging is open or damaged, the expiry date has passed or the contents appear abnormal.

The syringe and needles are intended for single use only. They must not be reused or resterilised. Any remaining material and all used equipment must be disposed of as appropriate clinical waste.

Order Monalisa Mild

Monalisa Mild with Lidocaine is available from The Clinic Vault for eligible professional purchasers. Customers are responsible for confirming that they possess the qualifications, training, insurance and legal authority required to purchase and administer injectable aesthetic products.

Explore our professional aesthetic product collection or review the Genoss instructions-for-use library for available manufacturer documentation.

Professional-use notice: This page provides general product information. It does not replace the instructions supplied with the product, accredited clinical training, local regulations, professional judgement or an individual patient assessment.